PMC2828414_01
PMC2828414_02
Metabolic response of one patient treated with imatinib mesylate. Comparison of FDG PET imaging pre- (a, b) and post- (c, d) three months of therapy.
1471-2407-10-22-1.jpg
PMC2828414_02_1471-2407-10-22-1.jpg
F1
The FDG PET scan images documenting the metabolic response of one patient are illustrated in Figure 1.
Local progression-free survival of all surgically treated chordoma patients.
1471-2407-10-22-2.jpg
PMC2828414_02_1471-2407-10-22-2.jpg
F2
Overall survival of the entire series of 25 chordoma patients.
1471-2407-10-22-3.jpg
PMC2828414_02_1471-2407-10-22-3.jpg
F3
The 5-year and 10-year survival rate of the entire series was 76.7% and 59.7%, respectively (Figure 3).